This resolution declares September 12, 2026, as Recovery Day in Michigan to honor individuals working toward long-term sobriety and the organizations that support them. It highlights the gap between the number of residents with substance use disorders and those receiving treatment, emphasizing the role of recovery community groups in providing ongoing assistance at a lower cost than clinical care. The measure also directs that a copy of the resolution be sent to the Blue Water Recovery and Outreach Center as a gesture of appreciation.
This bill is a procedural resolution that proclaims September 2026 as Recovery Month in California. It aims to honor individuals in recovery, service providers, and communities dedicated to treating substance use disorders and mental health conditions. The text also highlights recent state investments under Proposition 1, which have funded new behavioral health facilities and treatment slots across the state.
The Campus Lifeline Act expands federal grant programs to support student-led mental health and substance use disorder interventions at institutions of higher education. It authorizes funding for peer awareness activities, such as suicide prevention education and digital campaigns that encourage students to seek help, while requiring grantees to provide accessible resources for online and distance-learning students. Additionally, the bill directs the National Suicide Prevention Lifeline program to coordinate with schools and universities to list hotline numbers on student identification cards and promote behavioral health resources through public service announcements.
The RCORP Authorization Act establishes a new program to provide funding for preventing, treating, and recovering from opioid and other substance use disorders in rural areas. This program allows the Health Resources and Services Administration to award grants to states, tribal organizations, and other eligible entities for up to five years. The funds can be used for planning, implementing evidence-based treatment models, addressing emerging public health issues, and providing technical assistance, but they cannot be used to buy or improve real property. The legislation authorizes $165 million annually for each fiscal year from 2027 through 2031 to support these efforts.
The Virtual-Based Opioid Treatment for Veterans Act directs the Department of Veterans Affairs to launch a two-year pilot program aimed at expanding access to virtual opioid treatment for enrolled veterans who face barriers to in-person care. This initiative requires the VA to conduct outreach, build referral networks, and coordinate with other federal agencies to connect veterans with telehealth programs that combine medication and counseling in a single visit. The bill also mandates a study on treatment barriers and requires annual reports to Congress on the program's progress until the opioid crisis is no longer considered a public health emergency.
SB 1117 amends the Michigan Mental Health Code to update and clarify the definitions of key terms used in state psychiatric hospitals and related services. The bill directly affects individuals receiving mental health or substance use disorder services, as well as the facilities and staff that provide them. It revises definitions for categories such as serious emotional disturbance, serious mental illness, telemedicine, and transfer facilities to ensure consistency with current medical standards and operational realities. By standardizing these terms, the legislation aims to improve clarity in how services are delivered and funded across the state's mental health system.
This bill amends Massachusetts law to expand who can access certain substance use disorder treatment services beyond just blood relatives. It specifically adds parents, as defined by a 2024 act, and other family members recognized by law to the list of eligible individuals. The change ensures that a broader range of family members can utilize these treatment resources without needing to prove a biological connection.
The Turn the Tide Act primarily increases federal funding for substance use disorder treatment, prevention, and recovery services, directing billions of dollars to states, tribes, and local organizations for the years 2027 through 2030. Key provisions include expanding Medicaid coverage for mental health and behavioral health services, removing insurance barriers to medication-assisted treatment, and limiting cost-sharing requirements for opioid overdose reversal medications. The bill also establishes new grant programs to support recovery housing, train first responders, and assist law enforcement with mental health and wellness initiatives. Additionally, it targets funding toward states with the highest rates of drug overdose deaths and extends existing waivers to improve Medicaid delivery systems in those areas.
The Expanding Opportunities for Recovery Act of 2026 directs federal funding to states to improve access to opioid addiction treatment for individuals who lack health insurance or face coverage barriers. These grants must be managed by state substance abuse agencies and used to provide evidence-based services, such as medication-assisted treatment, based on medical recommendations. The legislation explicitly limits grant funds to cover no more than 60 consecutive days of treatment per person and requires states to report data on treatment outcomes and usage. Additionally, the bill mandates that the federal government evaluate the program's effectiveness and share results publicly while offering technical assistance to participating states.
The Modernizing Opioid Treatment Access Act 2.0 of 2026 allows specific addiction medicine specialists to prescribe methadone for opioid use disorder to be dispensed directly through pharmacies, rather than requiring patients to attend traditional treatment clinics. This change permits these qualified doctors to use telemedicine for patient care and requires that the methadone be in a liquid or dispersible tablet form. While the bill maintains existing clinic-based treatment options, it streamlines access by removing the need for pharmacies to obtain separate registrations to dispense the medication. The law also mandates that patients sign informed consent forms explaining how privacy rules differ between clinic and pharmacy settings, and it requires the Drug Enforcement Administration to report on the program's progress to Congress every year.